Strategic Cooperation between GeneQuantum Healthcare and Biocytogen on Development of Antitumor Bioconjugates
SUZHOU, China, 11 March 2021-- GeneQuantum Healthcare (GQ) today announced that the China National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for GQ1001, an in-house developed next generation antibody drug conjugate (ADC) asset. GQ1001 is the first site-specific ADC produced using GQ’s intelligent ligase-dependent conjugation (iLDC) technology platform. GQ1001 has already received Clinical Trial approval from the Therapeutic Goods Administration (TGA) in Australia and IND from FDA in USA.
“GQ1001 is a project specially funded by National Science and Technology Major Project of the Ministry of Science and Technology of China. The patients have been enrolled into a multi-center Phase I, dose escalation trial in the United States and Australia. The NMPA's IND approval is not only an important leap forward in GQ’s global development plans for GQ1001, but also a demonstration of acceptance that GQ’s iLDC platform has been accepted by multi-country drug authorities. GQ successfully developed this technology to address the challenges during process and manufacturing of ADC industry. It demonstrates that China is leading in this area.” Said by Dr. Gang Qin, founder/CEO of GeneQuantum.
About GeneQuantum Healthcare
GeneQuantum Healthcare (Suzhou) Co., Ltd. is a high-tech biopharmaceutical company dedicated to the development of innovative biotherapeutics, with the goal to become a globally competitive leader in bio-pharmaceuticals. The company possesses innovative and patented iLDC (intellectual Ligase Dependent Conjugation) technical platform, focuses on next generation site-specific bioconjugate development, and aim to address the unmet medical needs of global cancer patients.
Forward-looking Statement
Any forward-looking statements in this announcement are based upon information available to GeneQuantum and/or their respective board of directors at the time, as the case may be, as of the date of this announcement and, while believed to be true when made, may ultimately prove to be incorrect. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Subject to any obligations under applicable law, none of GeneQuantum or any member of their respective board of directors undertakes any obligation to update any forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations.